ArticleCureus2025
An Immunocompetent Host With Severe Disseminated Herpes Simplex Virus Type 2 Infection With Hepatorenal Involvement.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Herpes simplex virus type 2 (HSV-2) most commonly causes localized mucocutaneous infections, whereas disseminated disease with visceral involvement is rare, particularly in immunocompetent individuals. HSV hepatitis is a potentially life-threatening manifestation that often presents with nonspecific symptoms and markedly elevated liver enzymes, making early recognition difficult. We report a 58-year-old immunocompetent man with good performance status (Eastern Cooperative Oncology Group (ECOG) 0) who presented with fever, malaise, and a progressive vesicular rash involving the face, hands, and trunk. Laboratory investigations revealed elevated transaminases, hyperbilirubinemia, acute kidney injury, and electrolyte abnormalities. Imaging demonstrated mild hepatosplenomegaly without obstruction, and polymerase chain reaction testing confirmed HSV-2 in both serum and skin lesions. Other infectious and autoimmune evaluations were negative. The patient was treated with intravenous acyclovir followed by oral valacyclovir, resulting in complete resolution of symptoms and normalization of liver and renal function. Given ongoing high-risk sexual behavior, he was also counseled on long-acting injectable HIV pre-exposure prophylaxis with lenacapavir. The current case highlights that disseminated HSV-2 infection with hepatic and renal injury can occur in an immunocompetent host. Early recognition and prompt antiviral therapy are critical to improving clinical outcomes. Physicians should consider a high index of suspicion for HSV hepatitis in candidates presenting with unexplained transaminitis and systemic symptoms, even in the absence of classic mucocutaneous findings or immunosuppression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.